高剂量胰岛素优糖疗法在同时服用β-阻断剂和通道阻断剂过量时
Varun Roperia1, Ahmed Zia Kiani2, Naveen Jayakumar1
1Eisenhower Medical Center, Rancho Mirage, CA, USA.
概括
高剂量的胰岛素euglycemic治疗成功地管理了严重的β-阻断剂和通道阻断剂过量. 在这种治疗期间,仔细监测对于管理潜在的低血糖和低血糖至关重要.
科学领域:
- 心脏病学 心脏病学
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝塔阻断剂和通道阻断剂被广泛使用,导致频繁的过量服用.
- 过量服用会导致严重的心肌梗塞,收缩能力降低,血管扩张,导致耐药性低血压.
- 标准的血管压缩剂治疗在这些严重过量病例中往往是无效的.
研究的目的:
- 为了呈现同时服用β-阻断剂和通道阻断剂过量的一种病例.
- 为了证明使用高剂量胰岛素euglycemic治疗的耐药性低血压的成功管理.
- 为了强调在这种密集治疗过程中密切监测的重要性.
主要方法:
- 一个病例报告详细介绍了一名患者,他服用了结合β-阻断剂和通道阻断剂的过量.
- 用高剂量的胰岛素euglycemic疗法来治疗耐火性低血压.
- 持续监测不良影响,如低血糖和低血糖.
主要成果:
- 这位患者呈现出严重的血液动力学不稳定性,耐阻血管压缩剂.
- 开始高剂量胰岛素euglycemic治疗,并成功地稳定了患者的血液动力学.
- 通过频繁的监测和适当的干预措施来管理不良影响.
结论:
- 高剂量的胰岛素euglycemic治疗是严重β-阻断剂和通道阻断剂过量治疗的有效方法.
- 密切的患者监测对于这种治疗的安全和有效应用至关重要.
- 这种方法为在传统治疗失败时管理危及生命的过量服用提供了可行的选择.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
265
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
265
Heart Failure Drugs: Inotropic Agents
739
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
739
Hypoglycemia and Glucagon
349
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
349
Antihypertensive Drugs: Action of Calcium Channel Blockers
784
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
784
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
702
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
702
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.8K


